サマリー

市場分析と洞察：婦人科疾患治療薬の世界市場
世界の婦人科疾患治療薬市場は、2022年の181億7000万米ドルに比べ、2023年にはプラス成長で1億8890万米ドルに達すると予測される。川下産業からの需要の増加を背景に、婦人科疾患治療薬産業は2029年には2億4,000万米ドルに達すると評価されている。2023年から2029年までのCAGRは4.1%である。
女性人口の増加と女性に対する競争圧力の高まりが市場の成長を後押ししている。

レポートの対象
本レポートは、2018年から2029年までの世界の婦人科疾患治療薬市場の概観を紹介し、読者が世界の婦人科疾患治療薬市場を多角的に包括的に理解することを目的としています。2018年から2029年までの地域別収益、2018年から2023年までの企業の収益と粗利益率などの項目を分析しています。さらに、2018年から2029年までの各地域における製品タイプおよび用途の収益も取り上げています。

レポート掲載企業、タイプ、チャネル、地域
企業別
バイエル
ファイザー
サノフィ
富士ファーマ
エデンブリッジ製薬
ルパン
アドルシア・バイオシューティクス
デュシュネイ
ペリゴ
プレステージ・コンシューマー・ヘルスケア
コム インコーポレイテッド
フェムコープ
北京同仁堂
前金製薬
エンウェイ製薬
雲南白耀
タイプ別セグメント
中国特許薬
化学合成医薬品
チャネル別セグメント
病院
薬局
オンライン
地域別
北米
アメリカ
カナダ
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
北欧諸国
その他の欧州諸国
中国
アジア（中国を除く）
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ、中東、アフリカ
ブラジル
メキシコ
トルコ
イスラエル
GCC諸国

章の概要
第1章：製品定義、タイプ、チャネル紹介
第2章 2018年から2029年までの地域別収益分析
第3章：製品名企業の競争環境、収益、市場シェア、業界ランキング、最新の開発計画、合併・買収情報などの詳細分析
第4章 2018年から2029年までの世界のタイプ別製品収益分析
第5章 2018年から2029年までの世界のチャネル別製品収益分析
第6章：米国・カナダにおける2018年から2029年までのタイプ別・チャネル別製品収益分析2018年から2029年までの米国＆カナダにおける各国の製品収益分析
第7章：2018年から2029年までの欧州におけるタイプ別およびチャネル別の製品収益分析。2018年から2029年までの欧州各国の製品収益分析
第8章：2018年から2029年までの中国のタイプ別およびチャネル別製品収益分析。2018年から2029年までの中国の製品収益分析
第9章：2018年から2029年までのアジア（中国を除く）におけるタイプ別およびチャネル別の製品収益分析。2018年から2029年までのアジア（中国を除く）の各国の製品収益分析
第10章：2018年から2029年までの中東、アフリカ、ラテンアメリカにおけるタイプ別およびチャネル別の製品収益分析。2018年から2029年までの中東、アフリカ、中南米の各国の製品収益分析
第11章：企業概要：企業の基本情報、主要事業、婦人科疾患治療薬の紹介など。2018年から2023年までの各社の婦人科疾患治療薬の売上高とグロスマージン
第12章：婦人科疾患治療薬に関するQYResearchの結論
第13章：QYResearchが採用した方法論とデータソース

ページTOPに戻る

目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gynecological Conditions Medications Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Chinese Patent Medicine
1.2.3 Chemical Synthesis Medicine
1.3 Market by Channel
1.3.1 Global Gynecological Conditions Medications Market Size Growth Rate by Channel, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Online
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gynecological Conditions Medications Market Perspective (2018-2029)
2.2 Global Gynecological Conditions Medications Growth Trends by Region
2.2.1 Gynecological Conditions Medications Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Gynecological Conditions Medications Historic Market Size by Region (2018-2023)
2.2.3 Gynecological Conditions Medications Forecasted Market Size by Region (2024-2029)
2.3 Gynecological Conditions Medications Market Dynamics
2.3.1 Gynecological Conditions Medications Industry Trends
2.3.2 Gynecological Conditions Medications Market Drivers
2.3.3 Gynecological Conditions Medications Market Challenges
2.3.4 Gynecological Conditions Medications Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Gynecological Conditions Medications by Players
3.1.1 Global Gynecological Conditions Medications Revenue by Players (2018-2023)
3.1.2 Global Gynecological Conditions Medications Revenue Market Share by Players (2018-2023)
3.2 Global Gynecological Conditions Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Gynecological Conditions Medications, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Gynecological Conditions Medications Market Concentration Ratio
3.4.1 Global Gynecological Conditions Medications Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gynecological Conditions Medications Revenue in 2022
3.5 Global Key Players of Gynecological Conditions Medications Head office and Area Served
3.6 Global Key Players of Gynecological Conditions Medications, Product and Application
3.7 Global Key Players of Gynecological Conditions Medications, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gynecological Conditions Medications Breakdown Data by Type
4.1 Global Gynecological Conditions Medications Historic Market Size by Type (2018-2023)
4.2 Global Gynecological Conditions Medications Forecasted Market Size by Type (2024-2029)
5 Gynecological Conditions Medications Breakdown Data by Channel
5.1 Global Gynecological Conditions Medications Historic Market Size by Channel (2018-2023)
5.2 Global Gynecological Conditions Medications Forecasted Market Size by Channel (2024-2029)
6 North America
6.1 North America Gynecological Conditions Medications Market Size (2018-2029)
6.2 North America Gynecological Conditions Medications Market Size by Type
6.2.1 North America Gynecological Conditions Medications Market Size by Type (2018-2023)
6.2.2 North America Gynecological Conditions Medications Market Size by Type (2024-2029)
6.2.3 North America Gynecological Conditions Medications Market Share by Type (2018-2029)
6.3 North America Gynecological Conditions Medications Market Size by Channel
6.3.1 North America Gynecological Conditions Medications Market Size by Channel (2018-2023)
6.3.2 North America Gynecological Conditions Medications Market Size by Channel (2024-2029)
6.3.3 North America Gynecological Conditions Medications Market Share by Channel (2018-2029)
6.4 North America Gynecological Conditions Medications Market Size by Country
6.4.1 North America Gynecological Conditions Medications Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Gynecological Conditions Medications Market Size by Country (2018-2023)
6.4.3 North America Gynecological Conditions Medications Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Gynecological Conditions Medications Market Size (2018-2029)
7.2 Europe Gynecological Conditions Medications Market Size by Type
7.2.1 Europe Gynecological Conditions Medications Market Size by Type (2018-2023)
7.2.2 Europe Gynecological Conditions Medications Market Size by Type (2024-2029)
7.2.3 Europe Gynecological Conditions Medications Market Share by Type (2018-2029)
7.3 Europe Gynecological Conditions Medications Market Size by Channel
7.3.1 Europe Gynecological Conditions Medications Market Size by Channel (2018-2023)
7.3.2 Europe Gynecological Conditions Medications Market Size by Channel (2024-2029)
7.3.3 Europe Gynecological Conditions Medications Market Share by Channel (2018-2029)
7.4 Europe Gynecological Conditions Medications Market Size by Country
7.4.1 Europe Gynecological Conditions Medications Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Gynecological Conditions Medications Market Size by Country (2018-2023)
7.4.3 Europe Gynecological Conditions Medications Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Gynecological Conditions Medications Market Size (2018-2029)
8.2 China Gynecological Conditions Medications Market Size by Type
8.2.1 China Gynecological Conditions Medications Market Size by Type (2018-2023)
8.2.2 China Gynecological Conditions Medications Market Size by Type (2024-2029)
8.2.3 China Gynecological Conditions Medications Market Share by Type (2018-2029)
8.3 China Gynecological Conditions Medications Market Size by Channel
8.3.1 China Gynecological Conditions Medications Market Size by Channel (2018-2023)
8.3.2 China Gynecological Conditions Medications Market Size by Channel (2024-2029)
8.3.3 China Gynecological Conditions Medications Market Share by Channel (2018-2029)
9 Asia (excluding China)
9.1 Asia Gynecological Conditions Medications Market Size (2018-2029)
9.2 Asia Gynecological Conditions Medications Market Size by Type
9.2.1 Asia Gynecological Conditions Medications Market Size by Type (2018-2023)
9.2.2 Asia Gynecological Conditions Medications Market Size by Type (2024-2029)
9.2.3 Asia Gynecological Conditions Medications Market Share by Type (2018-2029)
9.3 Asia Gynecological Conditions Medications Market Size by Channel
9.3.1 Asia Gynecological Conditions Medications Market Size by Channel (2018-2023)
9.3.2 Asia Gynecological Conditions Medications Market Size by Channel (2024-2029)
9.3.3 Asia Gynecological Conditions Medications Market Share by Channel (2018-2029)
9.4 Asia Gynecological Conditions Medications Market Size by Region
9.4.1 Asia Gynecological Conditions Medications Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Gynecological Conditions Medications Market Size by Region (2018-2023)
9.4.3 Asia Gynecological Conditions Medications Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Size by Type
10.2.1 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Size by Channel
10.3.1 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Size by Channel (2018-2023)
10.3.2 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Size by Channel (2024-2029)
10.3.3 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Share by Channel (2018-2029)
10.4 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Size by Country
10.4.1 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Gynecological Conditions Medications Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Gynecological Conditions Medications Introduction
11.1.4 Bayer Revenue in Gynecological Conditions Medications Business (2018-2023)
11.1.5 Bayer Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Gynecological Conditions Medications Introduction
11.2.4 Pfizer Revenue in Gynecological Conditions Medications Business (2018-2023)
11.2.5 Pfizer Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Gynecological Conditions Medications Introduction
11.3.4 Sanofi Revenue in Gynecological Conditions Medications Business (2018-2023)
11.3.5 Sanofi Recent Developments
11.4 Fuji Pharma
11.4.1 Fuji Pharma Company Details
11.4.2 Fuji Pharma Business Overview
11.4.3 Fuji Pharma Gynecological Conditions Medications Introduction
11.4.4 Fuji Pharma Revenue in Gynecological Conditions Medications Business (2018-2023)
11.4.5 Fuji Pharma Recent Developments
11.5 Edenbridge Pharmaceuticals
11.5.1 Edenbridge Pharmaceuticals Company Details
11.5.2 Edenbridge Pharmaceuticals Business Overview
11.5.3 Edenbridge Pharmaceuticals Gynecological Conditions Medications Introduction
11.5.4 Edenbridge Pharmaceuticals Revenue in Gynecological Conditions Medications Business (2018-2023)
11.5.5 Edenbridge Pharmaceuticals Recent Developments
11.6 Lupin
11.6.1 Lupin Company Details
11.6.2 Lupin Business Overview
11.6.3 Lupin Gynecological Conditions Medications Introduction
11.6.4 Lupin Revenue in Gynecological Conditions Medications Business (2018-2023)
11.6.5 Lupin Recent Developments
11.7 Adorshea Bioceutics
11.7.1 Adorshea Bioceutics Company Details
11.7.2 Adorshea Bioceutics Business Overview
11.7.3 Adorshea Bioceutics Gynecological Conditions Medications Introduction
11.7.4 Adorshea Bioceutics Revenue in Gynecological Conditions Medications Business (2018-2023)
11.7.5 Adorshea Bioceutics Recent Developments
11.8 Duchesnay
11.8.1 Duchesnay Company Details
11.8.2 Duchesnay Business Overview
11.8.3 Duchesnay Gynecological Conditions Medications Introduction
11.8.4 Duchesnay Revenue in Gynecological Conditions Medications Business (2018-2023)
11.8.5 Duchesnay Recent Developments
11.9 Perrigo
11.9.1 Perrigo Company Details
11.9.2 Perrigo Business Overview
11.9.3 Perrigo Gynecological Conditions Medications Introduction
11.9.4 Perrigo Revenue in Gynecological Conditions Medications Business (2018-2023)
11.9.5 Perrigo Recent Developments
11.10 Prestige Consumer Healthcare
11.10.1 Prestige Consumer Healthcare Company Details
11.10.2 Prestige Consumer Healthcare Business Overview
11.10.3 Prestige Consumer Healthcare Gynecological Conditions Medications Introduction
11.10.4 Prestige Consumer Healthcare Revenue in Gynecological Conditions Medications Business (2018-2023)
11.10.5 Prestige Consumer Healthcare Recent Developments
11.11 Combe Incorporated
11.11.1 Combe Incorporated Company Details
11.11.2 Combe Incorporated Business Overview
11.11.3 Combe Incorporated Gynecological Conditions Medications Introduction
11.11.4 Combe Incorporated Revenue in Gynecological Conditions Medications Business (2018-2023)
11.11.5 Combe Incorporated Recent Developments
11.12 Femcorp
11.12.1 Femcorp Company Details
11.12.2 Femcorp Business Overview
11.12.3 Femcorp Gynecological Conditions Medications Introduction
11.12.4 Femcorp Revenue in Gynecological Conditions Medications Business (2018-2023)
11.12.5 Femcorp Recent Developments
11.13 Beijing Tongrentang
11.13.1 Beijing Tongrentang Company Details
11.13.2 Beijing Tongrentang Business Overview
11.13.3 Beijing Tongrentang Gynecological Conditions Medications Introduction
11.13.4 Beijing Tongrentang Revenue in Gynecological Conditions Medications Business (2018-2023)
11.13.5 Beijing Tongrentang Recent Developments
11.14 Qianjin Pharmaceutical
11.14.1 Qianjin Pharmaceutical Company Details
11.14.2 Qianjin Pharmaceutical Business Overview
11.14.3 Qianjin Pharmaceutical Gynecological Conditions Medications Introduction
11.14.4 Qianjin Pharmaceutical Revenue in Gynecological Conditions Medications Business (2018-2023)
11.14.5 Qianjin Pharmaceutical Recent Developments
11.15 Enwei Pharmaceutical
11.15.1 Enwei Pharmaceutical Company Details
11.15.2 Enwei Pharmaceutical Business Overview
11.15.3 Enwei Pharmaceutical Gynecological Conditions Medications Introduction
11.15.4 Enwei Pharmaceutical Revenue in Gynecological Conditions Medications Business (2018-2023)
11.15.5 Enwei Pharmaceutical Recent Developments
11.16 Yunnan Baiyao
11.16.1 Yunnan Baiyao Company Details
11.16.2 Yunnan Baiyao Business Overview
11.16.3 Yunnan Baiyao Gynecological Conditions Medications Introduction
11.16.4 Yunnan Baiyao Revenue in Gynecological Conditions Medications Business (2018-2023)
11.16.5 Yunnan Baiyao Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details